Nanoform has issued multiple term sheets for Nanoenzalutamide, aiming to maximize value. The company's technology is well-differentiated after years of development. Expectations for new GMP deals in the next quarters are positive, with high-quality term sheets aligning with assumptions.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing